From adrenoceptor mechanisms to clinical therapeutics: Raymond Ahlquist, Ph.D., 1914-1983.
Identification of two distinct types of adrenotropic receptors, alpha and beta, by Raymond Ahlquist provided the scientific basis that enabled the development of drugs to selectively block adrenoceptor function. These pharmacotherapeutic advances have improved the care of patients with coronary and hypertensive cardiovascular disease.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D002309:Cardiology / Q000266:history; D002395:Catecholamines / Q000502:physiology; D049673:History, 20th Century; D006801:Humans; D011941:Receptors, Adrenergic / Q000502:physiology; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D011943:Receptors, Adrenergic, beta / Q000502:physiology; D014481:United States
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D011941:Receptors, Adrenergic; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta